Trend Towards Favorable DFS Observed With Cisplatin/Paclitaxel in HRD Advanced Ovarian Cancer
Advanced Ovarian Cancer | Image Credit: © Katsyarina – stock.adobe.com The addition of paclitaxel to cisplatin did not increase perioperative morbidity and showed a trend towards longer disease-free survival (DFS) vs cisplatin alone during hyperthermic intraperitoneal chemotherapy (HIPEC) with interval debulking surgery (IDS) in patients with advanced-stage ovarian cancer, according to data from a retrospective … Read more